Dogs without concurrent diseases were more likely to receive IGla300 q24h than dogs with concurrent diseases (72% vs 50%, respectively; P = .04). Conclusions and Clinical Importance Insulin glargine 300 U/mL can be considered a suitable therapeutic option for once-daily administration in ...
Figure 1. Flow of Participants in a Trial of Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec for Type 2 DiabetesView LargeDownload There were no study- or country-level important protocol deviations during the trial. There were 26 important site-level protocol deviations, 68 at the ...
with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A post hoc analysis of ONWARDS 6" published in Diabetes, Obesity & Metabolism explores the impact of physical activity on hypoglycemia risk in adults with type 1 diabetes receiving different insulin...
一天一次地特胰岛素控制空腹血糖的疗效和安全性评价 the effecfiveness and safety of once daily insulin detemir to control fasting ・6 6 9 ・・药物研究动态・一天一次地特胰岛素控制空腹血糖的疗效和安全性评价邹大进【摘要1F P G 对糖尿病患者整体血糖水平和心脑血管糖尿病并发症的防治都至关重要。 地特...
Conclusions: These results demonstrate that insulin concentrations are equivalent during the last four hours of a 24-hour period when insulin glargine is administered once- or twice-daily. These findings do not support a role for twice-daily insulin glargine in the management of patients with type...
Insulin icodec is a basal insulin in development for once-weekly (OW) dosing. The aim of this study was to compare the hypoglycemia frequency and response after icodec vs. insulin glargine U100 (
Once-daily injections provided insufficient circulating insulin after the evening meal, while twice-daily injections did not last through the night. Plasma C peptide, indicating residual endogenous insulin secretion, was just detectable in two children but easily detectable in four children, whose 24-...
Effects of twice-daily Vs. once-daily slow release tacrolimus on the insulin resistance indexes in kidney transplant patientsV., CademartoriF., MassarinoE.L., ParodiR., RussoA., SofiaI., FontanaG.L., VivianiG., Garibotto
Aims: To evaluate 0.75 mg of dulaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, compared with once-daily insulin glargine for glycaemic control in Japanese patients with type 2 diabetes (T2D). 机译:目的:为了评估0.75 mg的度拉鲁肽(一种每周一次的胰高血糖素样肽-1受体激动剂)...
betes, who were randomized (1:1) and treated with insulin detemir (Levemir; Novo Nordisk, Bagsværd, Denmark) as add- ontherapy to oral glucose-lowering drugs, once- or twice-daily dosing. The trial was conducted in accordance with the Dec- laration of Helsinki and principles for Good...